Biogen Inc. (NASDAQ: BIIB) announced results from its Phase 2 CELIA study of diranersen, an investigational antisense oligonucleotide therapy targeting ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE